Metformin and Cancer, an Ambiguanidous Relationship.
View / Open Files
Authors
Skuli, Sarah J
Bakayoko, A'ishah
Skuli, Nicolas
Publication Date
2022-05-19ISSN
1424-8247
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Skuli, S. J., Alomari, S., Gaitsch, H., Bakayoko, A., Skuli, N., & Tyler, B. M. (2022). Metformin and Cancer, an Ambiguanidous Relationship.. https://doi.org/10.3390/ph15050626
Abstract
The deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus, drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous reports demonstrate that the widely used normoglycemic agent, metformin, can decrease the risk of cancer in type 2 diabetics and inhibit cell growth in various cancers, including pancreatic, colon, prostate, ovarian, and breast cancer. While metformin is a known adenosine monophosphate-activated protein kinase (AMPK) agonist and an inhibitor of the electron transport chain complex I, its mechanism of action in cancer cells as well as its effect on cancer metabolism is not clearly established. In this review, we will give an update on the role of metformin as an antitumoral agent and detail relevant evidence on the potential use and mechanisms of action of metformin in cancer. Analyzing antitumoral, signaling, and metabolic impacts of metformin on cancer cells may provide promising new therapeutic strategies in oncology.
Keywords
Diabetes, Therapeutics, Metformin, PI3K, Ampk, Cancer Metabolism, Drug Repurposing
Identifiers
35631452, PMC9144507
External DOI: https://doi.org/10.3390/ph15050626
This record's URL: https://www.repository.cam.ac.uk/handle/1810/338545
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.